Latest Market News

McLaren Minerals’ Pre-Feasibility Study confirms a robust, low-risk titanium mining project in Western Australia, projecting nearly A$900 million EBITDA over 16 years. The study highlights strong market demand and validated processing methods, setting the stage for the next development phase.

Whitefield Income Limited has announced fully franked monthly dividends for the first quarter of 2026, alongside a half yearly top-up dividend, delivering a solid yield based on recent share prices.

Catalina Resources has strategically reshaped its portfolio by acquiring the Breakaway Dam copper project and the Auric North gold portfolio, while divesting its Laverton assets to sharpen its focus on scalable growth opportunities.

L1 Group Limited reported a $700 million increase in assets under management for the December quarter, driven by strong inflows and positive returns, while performance fees are expected to reach nearly $39 million.

Amanda Lacaze, the CEO who transformed Lynas Rare Earths from a struggling startup to an ASX50 powerhouse, has announced her retirement. The company is now searching for a new leader to guide its next growth phase.

Perpetual Resources has reported multiple high-grade lithium rock chip assays from its Renaldinho and Morro Grande projects in Brazil, confirming a fertile lithium system and setting the stage for a significant drilling campaign in 2026.

Gold Mountain Limited has reported strong assay results from diamond drilling at its Irajuba IR-1 prospect in Brazil, extending known rare earth mineralisation beyond previous targets with notably high magnet rare earth oxide content.

Osmond Resources is fast-tracking development of its Orión EU Critical Minerals Project, with initial drilling confirming high-grade titanium, zircon, and rare earth elements. The company aims to complete a maiden Mineral Resource Estimate and Scoping Study by mid-2026.

AdAlta Limited has raised A$1.2 million through a strategic placement to advance its innovative PD1 armored MSLN CAR-T therapy for solid cancers, reinforcing its unique 'East to West' cellular immunotherapy approach.

Endeavour Group reports modest sales growth in the first half of FY26, driven by strong momentum at Dan Murphy’s and BWS, despite retail margin compression from price investments. Significant one-off costs related to warehouse changes weigh on profits.

GQG Partners reported a slight decline in funds under management to USD 163.9 billion at the end of 2025, despite significant net outflows, buoyed by strong investment performance throughout the year.

Tetratherix has successfully completed the second safety review of its TetraDerm clinical trial's second cohort, showing no adverse events and confirming a strong safety profile. The trial now progresses to its final phase, targeting a growing reconstructive surgery market.